PolyTherics Absorbs Antitope To Offer Cutting-Edge Drug Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s privately owned PolyTherics and Antitope have merged their biopharma services businesses to tap growing demand from big pharma for services and technologies used in the search for biologics such as antibody-drug conjugates.